Table 5.
Number of hemophilia patients from WAPPS‐Hemo switching between FIX concentrates
| FIX products | Switch to | Total | |||||
|---|---|---|---|---|---|---|---|
| Plasma‐derived | Recombinant | Recombinant glycoPEGylated | Recombinant Fc‐fusion protein | Recombinant albumin fusion protein | |||
| Switch from | Plasma‐derived | 4 | 1 | 0 | 11 | 1 | 17 |
| Recombinant | 0 | 1 | 1 | 22 | 7 | 31 | |
| Recombinant glycoPEGylated | 0 | 0 | 0 | 0 | 0 | 0 | |
| Recombinant Fc‐fusion protein | 1 | 0 | 1 | 0 | 5 | 7 | |
| Recombinant albumin fusion protein | 0 | 0 | 0 | 1 | 0 | 1 | |
| Total | 5 | 2 | 2 | 34 | 13 | 56 | |
FIX, factor IX; WAPPS, Web‐Accessible Population Pharmacokinetics Service.